This is a routine preclinical step for a development-stage biotech — positive but not transformative. No clinical trial timeline or financing update was provided. Watch for the next regulatory filing (510(k) or IDE) and any capital raise updates given the small market cap and cash-burn profile implied by the 20-F.
Price Chart
Executive Summary
Polyrizon announced successful completion of the biocompatibility evaluation program for its NASARIX Allergy Blocker nasal spray. All required biological safety tests (cytotoxicity, sensitization, irritation, pyrogenicity, acute systemic toxicity) met predetermined acceptance criteria, supporting advancement toward a first-in-human clinical trial. This is a preclinical milestone for a development-stage biotech with no revenue, representing incremental pipeline progress but not a value-inflection catalyst.
Key Facts
- Polyrizon (PLRZ) is a development-stage biotech with no revenue, market cap ~$24M.
- All required biocompatibility tests for NASARIX met acceptance criteria per ISO 10993, FDA guidance, and EU requirements.
- Tests included cytotoxicity, sensitization, irritation/intracutaneous reactivity, material-mediated pyrogenicity, and acute systemic toxicity.
- Long-term systemic toxicity assessed via toxicological risk assessment per ISO 10993-17 showing substantial safety margins.
- NASARIX is a drug-free mucoadhesive nasal spray for seasonal allergic rhinitis; still pre-clinical, no first-in-human trial date specified.
- Cross-filing: 20-F annual report filed ~99 days ago showed 1,608,266 ordinary shares outstanding as of Dec 31, 2025, with two reverse stock splits in 2025 (1-for-250 in May, 1-for-6 in Nov).
Financial Impact
No revenue or financial data disclosed. Pre-clinical milestone with no near-term commercialization path specified.
Risk Factors
- No first-in-human trial start date announced; clinical timelines remain uncertain.
- As a development-stage company, PLRZ requires ongoing financing; cash runway not disclosed in this filing.
- Two reverse stock splits in 2025 (1-for-250 and 1-for-6) reflect prior Nasdaq compliance challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-074946 |
| Document: ea0296863-6k_polyrizon.htm | 0001213900-26-074946 |
| Document: 0001213900-26-074946-index-headers.html | 0001213900-26-074946 |
| Document: 0001213900-26-074946-index.html | 0001213900-26-074946 |
| Document: 0001213900-26-074946.txt | 0001213900-26-074946 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.73 (−9.77%) |
Oct 2, 2026 24d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.73 (+9.21%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.73 (−18.15%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.73 (+19.95%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.38%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.38%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.73 (+22.38%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.73 (−15.29%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.73 (−36.57%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.73 (−36.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers